

Appl. No. 09/489,667  
Reply to Office Action of October 24, 2005

**BEST AVAILABLE COPY**

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-68. (Cancelled)

69. (Currently amended) An agent for treating pain comprising a modified elestridial botulinum neurotoxin comprising a botulinum neurotoxin H<sub>N</sub>, a botulinum neurotoxin L chain, and no functional H<sub>C</sub> domain, wherein the modified ~~elestridial neurotoxin is obtained by removing or modifying an HC domain of a native elestridial neurotoxin to form an intermediate elestridial neurotoxin and covalently coupling the modified botulinum neurotoxin being covalently coupled to substance P to the intermediate elestridial neurotoxin so that the modified elestridial botulinum neurotoxin no longer binds to botulinum neurotoxin receptors at a neuromuscular junction with the same affinity as the native elestridial botulinum neurotoxin.~~

70. (Cancelled)

71. (Currently amended) The agent of claim 69 wherein the elestridial botulinum neurotoxin is a botulinum toxin selected from the group consisting of serotype A, serotype B, serotype C<sub>1</sub>, serotype D, serotype E, serotype F and serotype G.

72. (Currently amended) The agent of claim 69 wherein the elestridial botulinum neurotoxin is botulinum toxin serotype A.

Appl. No. 09/489,667  
Reply to Office Action of October 24, 2005

**BEST AVAILABLE COPY**

73. (Currently amended) The agent of claim 69 wherein the ~~clostridial botulinum neurotoxin comprises an H<sub>N</sub> and an L chain~~ agent is a fusion protein.

74. (Cancelled)

75. (Currently amended) The agent of ~~claim 73~~ wherein the L chain is obtained from an organism selected from the group consisting of ~~Clostridial beratti, Clostridial butyricum, Clostridial botulinum, and Clostridial tetani~~ claim 69, wherein the L chain is obtained from a botulinum toxin selected from the group consisting of botulinum toxin serotype A, serotype B, serotype C<sub>1</sub>, serotype D, serotype E, serotype F and serotype G.

76. (Currently amended) The agent of ~~claim 73~~ claim 69, wherein the H<sub>N</sub> is obtained from a botulinum toxin selected from the group consisting of botulinum toxin serotype A, serotype B, serotype C<sub>1</sub>, serotype D, serotype E, serotype F and serotype G.

77. (Previously presented) An agent for treating pain comprising a botulinum toxin, without an H<sub>c</sub> that binds to receptors at the neuromuscular junction with the same affinity as native botulinum toxin, covalently coupled to substance P.

78. (Previously presented) An agent for treating pain comprising a botulinum toxin serotype A, without a functional H<sub>c</sub> domain, covalently coupled to substance P.

**BEST AVAILABLE COPY**

Appl. No. 09/489,667  
Reply to Office Action of October 24, 2005

79. (Previously presented) An agent for treating pain comprising a botulinum toxin covalently coupled to substance P, wherein an H<sub>c</sub> of the toxin has been removed.

80. (Previously presented) An agent for treating pain comprising a botulinum toxin serotype A covalently coupled to substance P, wherein an H<sub>c</sub> of the toxin has been removed, the agent treats pain by acting on a projection neuron.